Niagen Bioscience (NAGE)
Market Price (5/25/2026): $3.71 | Market Cap: $296.5 MilSector: Health Care | Industry: Biotechnology
Niagen Bioscience (NAGE)
Market Price (5/25/2026): $3.71Market Cap: $296.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Nutritional Supplements, and Longevity & Healthy Aging. | Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -132% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 66x Key risksNAGE key risks include [1] uncertain outcomes from its key clinical trials for conditions like Parkinson's disease, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.4% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -43% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, and Aging Population & Chronic Disease. Themes include Nutritional Supplements, and Longevity & Healthy Aging. |
| Weak multi-year price returns2Y Excs Rtn is -94%, 3Y Excs Rtn is -132% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 66x |
| Key risksNAGE key risks include [1] uncertain outcomes from its key clinical trials for conditions like Parkinson's disease, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Niagen Bioscience reported mixed First Quarter 2026 financial results on May 6, 2026, which included a significant one-time gain.
Net income reached $6.3 million for the quarter, largely buoyed by a $4.8 million gain from the divestiture of its Analytical Reference Standards and Services operating segment. Excluding this gain, core net income was substantially lower. Total net sales increased 3% to $31.5 million, slightly missing analysts' estimates of $31.58 million, and diluted earnings per share (EPS) of $0.07 were slightly below the consensus of $0.08. Following this announcement, the stock fell 7.44% since market close.
2. The company experienced a material increase in operating expenses and a shift to negative operating cash flow.
Operating expenses surged by 26%, or $3.8 million, to $18.4 million in Q1 2026, primarily driven by a 19% increase in sales and marketing expenses and a 40% jump in general and administrative costs. This aggressive spending, aimed at brand growth, contributed to a net cash outflow of $1.2 million from operating activities during the quarter, a significant decline from the $7.9 million net cash provided by operations in the prior year, mainly due to increased inventory and timing of receivables.
Show more
Stock Movement Drivers
Fundamental Drivers
The -38.9% change in NAGE stock from 1/31/2026 to 5/24/2026 was primarily driven by a -32.9% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5242026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.99 | 3.66 | -38.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 125 | 130 | 4.6% |
| Net Income Margin (%) | 16.4% | 14.3% | -12.8% |
| P/E Multiple | 23.4 | 15.7 | -32.9% |
| Shares Outstanding (Mil) | 80 | 80 | -0.2% |
| Cumulative Contribution | -38.9% |
Market Drivers
1/31/2026 to 5/24/2026| Return | Correlation | |
|---|---|---|
| NAGE | -38.9% | |
| Market (SPY) | 8.1% | 45.2% |
| Sector (XLV) | -2.7% | 20.0% |
Fundamental Drivers
The -51.5% change in NAGE stock from 10/31/2025 to 5/24/2026 was primarily driven by a -53.4% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5242026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.54 | 3.66 | -51.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 116 | 130 | 12.1% |
| Net Income Margin (%) | 15.2% | 14.3% | -6.3% |
| P/E Multiple | 33.7 | 15.7 | -53.4% |
| Shares Outstanding (Mil) | 79 | 80 | -0.8% |
| Cumulative Contribution | -51.5% |
Market Drivers
10/31/2025 to 5/24/2026| Return | Correlation | |
|---|---|---|
| NAGE | -51.5% | |
| Market (SPY) | 9.9% | 44.7% |
| Sector (XLV) | 4.8% | 23.9% |
Fundamental Drivers
The -53.4% change in NAGE stock from 4/30/2025 to 5/24/2026 was primarily driven by a -77.8% change in the company's P/E Multiple.| (LTM values as of) | 4302025 | 5242026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.85 | 3.66 | -53.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 100 | 130 | 30.9% |
| Net Income Margin (%) | 8.6% | 14.3% | 66.5% |
| P/E Multiple | 70.7 | 15.7 | -77.8% |
| Shares Outstanding (Mil) | 77 | 80 | -3.7% |
| Cumulative Contribution | -53.4% |
Market Drivers
4/30/2025 to 5/24/2026| Return | Correlation | |
|---|---|---|
| NAGE | -53.4% | |
| Market (SPY) | 36.0% | 39.4% |
| Sector (XLV) | 8.6% | 11.6% |
Fundamental Drivers
nullnull
Market Drivers
4/30/2023 to 5/24/2026| Return | Correlation | |
|---|---|---|
| NAGE | ||
| Market (SPY) | 86.3% | 47.5% |
| Sector (XLV) | 18.0% | 23.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NAGE Return | - | - | - | - | -18% | -40% | -51% |
| Peers Return | 5% | -42% | 60% | 26% | -7% | -17% | -5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| NAGE Win Rate | - | - | - | - | 40% | 20% | |
| Peers Win Rate | 53% | 27% | 62% | 50% | 42% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| NAGE Max Drawdown | - | - | - | - | - | -46% | |
| Peers Max Drawdown | -31% | -51% | -32% | -38% | -50% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, USNA, NATR, BRBR, LFVN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
NAGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
NAGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Niagen Bioscience (NAGE)
AI Analysis | Feedback
Here are a couple of brief analogies to describe ChromaDex Corporation (NAGE):
1. Think of it as the Intel of healthy aging supplements: they develop a proprietary, science-backed 'engine' (NIAGEN) for cellular health, which they both supply to other manufacturers and use to power their own premium TRU NIAGEN branded products sold directly to consumers.
2. Imagine a specialized BASF or DuPont for nutraceuticals: they discover and produce a unique healthy aging ingredient (NIAGEN) that they sell as raw material to other companies, while also marketing it in their own high-end TRU NIAGEN supplements direct to consumers.
AI Analysis | Feedback
- TRU NIAGEN Consumer Products: Finished dietary supplement products that contain the proprietary ingredient NIAGEN, sold directly to consumers and distributors.
- NIAGEN Ingredient: A proprietary nicotinamide riboside ingredient supplied as a raw material to manufacturers of other consumer products.
- IMMULINA: An ingredient consisting of Braun-type lipoproteins and spirulina extracts, used to support human immune function.
- Analytical Reference Standards and Services: Products and services provided for quality control of raw materials and consumer products across various industries.
AI Analysis | Feedback
ChromaDex Corporation (symbol: NAGE), which focuses on healthy aging bioscience, serves a diverse customer base, including direct sales to individuals and business-to-business (B2B) sales. Based on the provided information, the company sells its finished dietary supplement products, such as TRU NIAGEN, directly to consumers, making individual consumers a significant customer group.
The up to three categories of customers that ChromaDex Corporation primarily serves are:
-
Individual Consumers: These are the end-users who purchase ChromaDex's finished dietary supplement products, particularly TRU NIAGEN. Sales to this category occur directly through the company's proprietary e-commerce platform (TRUNIAGEN.com), as well as through major online marketplaces like Amazon and other internet marketplaces.
-
Retailers and Distributors: This category includes various businesses that purchase ChromaDex's finished consumer products (such as TRU NIAGEN) for resale. This encompasses online entities like Amazon (functioning as a reseller), other internet marketplaces, and physical specialty retailers.
-
Direct Healthcare Practitioners: These are healthcare professionals who purchase ChromaDex's finished consumer products to provide or recommend to their patients, acting as a channel to reach individual consumers.
ChromaDex also sells proprietary ingredients (e.g., NIAGEN, IMMULINA) as raw materials to "manufacturers of consumer products" and provides analytical reference standards and services to various industries (including dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals). However, the background information does not specify the names of these particular customer companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Robert Fried
Chief Executive Officer Mr. Fried has served as Chief Executive Officer of Niagen Bioscience (formerly ChromaDex) since April 2018, having previously been President and Chief Operating Officer since 2017. He initially joined ChromaDex's Board of Directors in 2015. Mr. Fried is a seasoned entrepreneur with a diverse background in entertainment and media. He founded Fried Films in 1990 and Spirit EMX LLC in 2007, the latter of which was acquired by Hallmark Cards. He also held the position of president and CEO of Savoy Pictures from 1994 to 1996. From 1996 to 2001, he was Chairman and CEO of WhatsHotNow, an e-commerce company that was sold to QVC. Earlier in his career, Mr. Fried held executive positions at major entertainment companies, including Executive Vice President of Production at Columbia Pictures and Director of Business Development at 20th Century Fox. He co-founded HealthSpan Research LLC in 2016, which ChromaDex acquired in 2017.James Lee
Interim Chief Financial Officer and Interim Principal Accounting Officer Mr. Lee was appointed Interim Chief Financial Officer and Interim Principal Accounting Officer of Niagen Bioscience (formerly ChromaDex) effective July 12, 2024. He has been with the company since January 2009, previously serving as Assistant Controller and Controller. Before joining ChromaDex, Mr. Lee held a managerial position in accounting at Samsung Electronics Co. Ltd. He earned a Bachelor of Arts in Architecture from the University of California, Berkeley, and an MBA from the University of Illinois Urbana-Champaign.Frank L. Jaksch Jr.
Co-Founder & Chairman of the Board Mr. Jaksch Jr. is a co-founder of Niagen Bioscience (formerly ChromaDex). He plays a key role in leading the company's research and strategic initiatives within both the pharmaceutical and nutraceutical industries.Andrew Shao, Ph.D.
SVP, Global Regulatory & Scientific Affairs Dr. Shao serves as the Senior Vice President of Global Regulatory & Scientific Affairs at Niagen Bioscience (formerly ChromaDex). He is recognized as a scientific leader within the company.AI Analysis | Feedback
The key risks to Niagen Bioscience (NAGE) are:-
High Reliance on Nicotinamide Riboside (NIAGEN) and Intellectual Property Protection
The company's core business, including its consumer products (TRU NIAGEN) and ingredient sales, is substantially dependent on nicotinamide riboside (NIAGEN) as its flagship ingredient and the broader market for NAD+ boosting products. The long-term success of Niagen Bioscience is intrinsically linked to the sustained scientific validation of NIAGEN and NAD+ for healthy aging, continuous consumer demand, and the strength and durability of its extensive patent portfolio (over 100 patents) that protects NIAGEN and other NAD+ precursors. A significant risk would arise from future scientific research questioning the efficacy or safety of NAD+ boosters, the expiration or invalidation of key patents protecting NIAGEN, or the emergence of intense competition with equally effective or lower-cost alternatives. -
Regulatory Risks
Niagen Bioscience operates in regulated industries, specifically dietary supplements and, increasingly, pharmaceuticals. Both sectors are subject to stringent and evolving regulatory oversight. Changes in regulations for dietary supplements by authorities such as the FDA, particularly concerning product claims, manufacturing practices, and permissible ingredients, could negatively impact the company's consumer product segment. For example, the FDA's position that nicotinamide mononucleotide (NMN) may not be sold as a dietary supplement highlights the dynamic regulatory landscape in the NAD+ precursor market. Furthermore, the development and commercialization of pharmaceutical-grade NIAGEN are subject to lengthy, costly, and inherently uncertain regulatory approval processes for drug development. -
Intense Market Competition
The healthy aging and longevity market is highly competitive and continues to expand rapidly. Niagen Bioscience faces substantial competition from a diverse range of companies offering other NAD+ precursors, various dietary supplements, nutraceuticals, and emerging pharmaceutical interventions aimed at promoting healthy aging. The company's ability to effectively differentiate its products, maintain or grow market share, and successfully penetrate new markets amidst this competitive landscape presents a continuous challenge.
AI Analysis | Feedback
nullAI Analysis | Feedback
ChromaDex Corporation (NAGE) operates in several addressable markets with its key products and services, primarily focusing on healthy aging. The company's main offerings include nicotinamide riboside (NIAGEN) and its consumer product TRU NIAGEN, the ingredient IMMULINA (spirulina extracts), and Analytical Reference Standards and Services.
Nicotinamide Riboside (NIAGEN) and NAD+ Supplements
The global market for Nicotinamide Riboside (NR) supplements, a key ingredient in NIAGEN and TRU NIAGEN, was valued at approximately USD 595 million in 2024 and is projected to reach USD 1.67 billion by 2033. Other estimates place the global NR market size at USD 1.81 billion in 2025, expected to grow to USD 3.23 billion by 2030. The broader NAD+ enhancer market was estimated at USD 1.00 billion in 2025 and is expected to reach USD 1.63 billion by 2032. For NAD+ Anti-Aging Nutraceuticals, the market size was USD 4.78 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 8.49% through 2033. North America is a dominant region in this market, with the Nicotinamide Riboside Supplements market in North America valued at approximately USD 225 million in 2024 and accounting for over 45% of the global NAD+ Enhancer market share in 2023.
IMMULINA (Spirulina Extracts)
The global spirulina market, which includes the extracts found in IMMULINA, was valued at USD 824.06 million in 2025. It is projected to grow to USD 1,995.25 million by 2034, exhibiting a CAGR of 10.39% during the forecast period. Another report estimates the global spirulina market size at USD 683.15 million in 2025, expected to reach USD 1,287.13 million by 2032, growing at a CAGR of 9.47%. North America holds a significant share, dominating the spirulina market with a 36.98% market share in 2025.
Analytical Reference Standards and Services
The global analytical standards market, which encompasses ChromaDex's Analytical Reference Standards and Services segment, was valued at USD 1.54 billion in 2025. It is projected to grow to USD 2.75 billion by 2034, with a CAGR of 6.69% during the forecast period. Other estimates for the global market include USD 1.52 billion in 2025, reaching USD 2.13 billion by 2031, and USD 1.46 billion in 2025, projected to reach USD 2.38 billion by 2033. North America is a significant market for analytical standards, holding a 39.20% revenue share in 2025 and estimated to grow at a CAGR of 8.9%. The United States is recognized as one of the most mature and technologically advanced Analytical Standards Markets globally.
AI Analysis | Feedback
Niagen Bioscience (NAGE) is expected to drive future revenue growth over the next 2-3 years through several key strategies, building on its position as a bioscience company focused on healthy aging and its proprietary NAD+ precursor, nicotinamide riboside (Niagen).
The primary drivers of future revenue growth include:
-
Continued Expansion of E-commerce and Direct-to-Consumer Sales: Niagen Bioscience anticipates sustained growth through its e-commerce platforms, including TRUNIAGEN.com and Amazon. The company's e-commerce segment has demonstrated robust performance, with significant year-over-year increases in net sales, which is expected to continue contributing to overall revenue growth.
-
Growth through Strategic Partnerships and Distribution Channels: The company is focused on leveraging established partnerships and forging new strategic collaborations to expand its market reach. A notable partnership granting access to over 8,000 medical and healthcare practitioners is expected to substantially boost Tru Niagen distributor revenues and enhance market penetration. Expanding market presence through various partnerships and product expansions remains a key strategy.
-
Commercialization and Expansion of the Niagen+ Product Line: The Niagen+ product line, featuring pharmaceutical-grade Niagen®, Niagen IV, and Niagen injections, is a significant growth driver. The company has been expanding the availability of these products to wellness clinics and plans to further extend distribution, including through its own telehealth platform and by leveraging e-commerce expertise to reach more patients. The introduction of new lifestyle drug-like products is anticipated to mark a pivotal growth phase.
-
Expansion into New NAD Market Applications: Niagen Bioscience is strategically positioning itself to capitalize on the rapidly expanding NAD market. This includes exploring and entering new application areas such as skincare, cosmetics, food, beverages, and pharmaceuticals. The company is also optimistic about the potential for Niagen products in specific health areas like the GLP-1 market and among Parkinson's patients. The launch of a Niagen® Skincare Innovation Lab and new dermatologically tested products further illustrates this expansion.
-
Focus on Core NAD Science and Intellectual Property: By divesting non-core activities, Niagen Bioscience is streamlining its operations to concentrate resources on NAD science, intellectual property, and commercial growth. This focus on its core scientific foundation and proprietary ingredients is expected to underpin the development of new products and services, creating additional revenue opportunities.
AI Analysis | Feedback
Share Repurchases
- Niagen Bioscience announced an Equity Buyback for $10 million worth of its shares on November 7, 2025.
Share Issuance
- In June 2025, stockholders approved an amendment to the 2017 Equity Incentive Plan to increase the number of shares available for issuance by 4.75 million shares of common stock.
- ChromaDex (now Niagen Bioscience) raised $7.7 million, net of offering costs, from Nestlé Health Science and existing strategic investors in October 2022.
Inbound Investments
- ChromaDex (now Niagen Bioscience) received $7.7 million in investment from Nestlé Health Science and existing strategic investors in October 2022.
Outbound Investments
- On December 22, 2025, Niagen Bioscience acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast.
- On February 24, 2026, Niagen Bioscience (formerly ChromaDex) sold its ChromaDex Reference Standards business to LGC (or VHG Labs, Inc.) in an all-cash transaction for approximately $6 million, as part of a strategy to exit non-core activities and focus on NAD+ science.
Capital Expenditures
- Cash used in investing activities, primarily capital expenditures, was $167,000 for the six months ended June 30, 2025, and $53,000 for the six months ended June 30, 2024.
- Cash used in investing activities was approximately $0.2 million for the nine months ended September 30, 2022, and $0.4 million for the nine months ended September 30, 2021.
- The primary focus of capital expenditures includes the development and expansion of operations and investments to protect intellectual property.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| With Niagen Bioscience Stock Sliding, Have You Assessed The Risk? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NAGE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.67 |
| Mkt Cap | 0.4 |
| Rev LTM | 708 |
| Op Inc LTM | 39 |
| FCF LTM | 14 |
| FCF 3Y Avg | 29 |
| CFO LTM | 24 |
| CFO 3Y Avg | 40 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.7% |
| Rev Chg Q | 2.5% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | -15.2% |
| Op Inc Chg 3Y Avg | 17.0% |
| Op Mgn LTM | 7.1% |
| Op Mgn 3Y Avg | 6.3% |
| QoQ Delta Op Mgn LTM | -0.5% |
| CFO/Rev LTM | 4.8% |
| CFO/Rev 3Y Avg | 6.7% |
| FCF/Rev LTM | 3.9% |
| FCF/Rev 3Y Avg | 4.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 0.4 |
| P/Op Inc | 8.9 |
| P/EBIT | 9.6 |
| P/E | 14.0 |
| P/CFO | 11.6 |
| Total Yield | 7.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 6.2% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -22.5% |
| 3M Rtn | -21.7% |
| 6M Rtn | -8.0% |
| 12M Rtn | -45.5% |
| 3Y Rtn | -22.2% |
| 1M Excs Rtn | -25.8% |
| 3M Excs Rtn | -32.5% |
| 6M Excs Rtn | -17.9% |
| 12M Excs Rtn | -73.8% |
| 3Y Excs Rtn | -110.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Consumer Products segment | 77 | 70 | 60 | 57 | |
| Ingredients segment | 20 | 11 | 9 | 7 | |
| Analytical Reference Standards and Services segment | 3 | 3 | 3 | 3 | |
| Corporate and other | 0 | 0 | 0 | ||
| Pharmaceuticals segment | 0 | ||||
| Total | 100 | 84 | 72 | 67 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Consumer Products segment | 17 | 14 | 7 | 6 | |
| Ingredients segment | 11 | 5 | 4 | 4 | |
| Analytical Reference Standards and Services segment | -0 | -1 | -0 | -0 | |
| Pharmaceuticals segment | -2 | ||||
| Corporate and other | -18 | -25 | -28 | -36 | |
| Total | 8 | -6 | -19 | -27 |
Price Behavior
| Market Price | $3.66 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 07/15/2008 | |
| Distance from 52W High | -74.6% | |
| 50 Days | 200 Days | |
| DMA Price | $4.80 | $8.16 |
| DMA Trend | down | down |
| Distance from DMA | -23.7% | -55.1% |
| 3M | 1YR | |
| Volatility | 53.3% | 52.8% |
| Downside Capture | 283.62 | 261.71 |
| Upside Capture | 96.01 | 63.66 |
| Correlation (SPY) | 44.4% | 37.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.05 | 1.60 | 1.61 | 1.55 | 1.72 | -0.18 |
| Up Beta | 1.42 | 1.59 | 1.47 | 1.63 | 2.48 | 0.15 |
| Down Beta | 7.28 | 1.66 | 1.59 | 1.08 | 1.04 | -0.77 |
| Up Capture | 171% | 136% | 118% | 112% | 102% | 19% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 21 | 29 | 56 | 119 | 134 |
| Down Capture | 561% | 177% | 199% | 183% | 163% | 94% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 21 | 33 | 66 | 126 | 138 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAGE | |
|---|---|---|---|---|
| NAGE | -63.6% | 53.2% | -1.71 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 11.6% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 38.3% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | -1.5% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -16.1% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 18.1% |
| Bitcoin (BTCUSD) | -31.3% | 41.8% | -0.78 | 22.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAGE | |
|---|---|---|---|---|
| NAGE | -13.7% | 56.7% | -0.90 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 23.7% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 47.5% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 0.9% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | -0.5% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 33.8% |
| Bitcoin (BTCUSD) | 11.6% | 55.3% | 0.41 | 26.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NAGE | |
|---|---|---|---|---|
| NAGE | -7.1% | 56.7% | -0.90 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 23.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 47.5% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 0.9% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | -0.5% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 33.8% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 26.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 03/04/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/04/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/08/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales Growth | 10.0% | 12.5% | 15.0% | 0 | 0 | Affirmed | Guidance: 12.5% for 2026 |
| 2026 General & Administrative Expense Increase | 3.00 Mil | 3.50 Mil | 4.00 Mil | -22.2% | Lowered | Guidance: 4.50 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net Sales Growth | 10.0% | 12.5% | 15.0% | -54.5% | -15.0% | Lowered | Guidance: 27.5% for 2025 |
| 2026 General & administrative expense increase | 4.00 Mil | 4.50 Mil | 5.00 Mil | -47.1% | Lowered | Guidance: 8.50 Mil for 2025 | |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.